Upadacitinib Is a Better Choice than Abrocitinib for Patients with Moderate-to-Severe Atopic Dermatitis: An Updated Meta-Analysis
Table 2
Results of primary outcomes.
Synthesis outcome
RCTs
No. of groups
Patients#
Evidence synthesis
I2(%)
value
Egger’s test
Grade
IGA responder (EOT)
JAK1 inhibitors
8
19
4349
OR 7.65 [5.52, 10.61]
70
<0.00001
0.6732
High
Abrocitinib
4
10
1598
OR 4.66 [3.40, 6.38]
19
<0.00001
0.9161
High
Upadacitinib
4
9
2751
OR 12.18 [8.40, 17.66]
63
<0.00001
0.4558
High
Subgroup differencea
93.3
0.0001
Abrocitinib (100 mg vs. 200 mg)
4
4
1177
OR 0.56 [0.44, 0.71]
0
<0.00001
0.7026
High
Upadacitinib (15 mg vs. 30 mg)
4
4
1757
OR 0.53 [0.44, 0.64]
0
<0.00001
0.7233
High
200 mg abrocitinib
4
4
908
OR 6.74 [4.54, 9.99]
0
<0.00001
0.0732
High
30 mg upadacitinib
4
4
1810
OR 16.20 [12.26, 21.42]
28
<0.00001
0.3356
High
Subgroup differenceb
90.8
0.0009
EASI-75 responder (EOT)
JAK1 inhibitors
8
19
4345
OR 8.73 [6.52, 11.68]
60
<0.00001
0.7506
High
Abrocitinib
4
10
1594
OR 6.86 [4.54, 10.37]
77
<0.00001
0.4755
High
Upadacitinib
4
9
2751
OR 10.74 [7.46, 15.46]
75
<0.00001
0.8377
High
Subgroup differencea
60.5
0.11
Abrocitinib (100 mg vs. 200 mg)
4
4
1177
OR 0.50 [0.39, 0.63]
0
<0.00001
0.3602
High
Upadacitinib (15 mg vs. 30 mg)
4
4
1757
OR 0.56 [0.45, 0.69]
0
<0.00001
0.3497
High
200 mg abrocitinib
4
4
907
OR 11.20 [5.73, 21.89]
66
<0.00001
0.0036
Moderate
30 mg upadacitinib
4
4
1810
OR 15.22 [9.96, 23.25]
64
<0.00001
0.5429
High
Subgroup differenceb
0
0.45
EASI-75 responder (after 2 weeks of treatment)
JAK1 inhibitors
7
16
4195
OR 8.36 [5.75, 12.15]
64
<0.00001
0.0598
High
Abrocitinib
4
10
1611
OR 5.64 [3.91, 8.14]
17
<0.00001
0.7995
High
Upadacitinib
3
6
2584
OR 13.45 [8.72, 20.75]
67
<0.00001
0.0056
Moderate
Subgroup differencea
90.2
0.001
Coloring mark means extremely magnitude of effect (OR ≤ 0.2 or OR ≥ 5). EOT = End of treatment. #Duplicate number of patients in the control group had been removed. value ≤0.05. aWe compare the efficacy between abrocitinib and upadacitinib, value <0.05 means upadacitinib has significantly better outcomes of IGA responder (EOT) and EASI-75 responder (after 2 weeks of treatment) than abrocitinib. bWe compare the most efficient dosage of two drugs, value <0.05 means 30 mg upadacitinib had significantly better outcomes of IGA responder (EOT) than 200 mg abrocitinib.
